FGP
LENZ

Freestone Grove Partners’s LENZ Therapeutics LENZ Stock Holding History

Freestone Grove Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18 Sell
2
-22,969
-100% -$323K ﹤0.01% 938
2025
Q4 		$368K Buy
+22,971
New +$670K ﹤0.01% 631

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Freestone Grove Partners's LENZ Position: Q1 2026 in Review

Freestone Grove Partners reduced its LENZ Therapeutics (LENZ) stake by 100% in Q1 2026, selling an estimated $323K and leaving 2 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Freestone Grove Partners first reported a position in LENZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $368K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Freestone Grove Partners held 2 shares of LENZ Therapeutics worth $18 as of Q1 2026.
  • Freestone Grove Partners sold 22,969 LENZ Therapeutics shares in Q1 2026, an estimated $323K.
  • LENZ Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #938 holding.
  • Freestone Grove Partners first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's LENZ Therapeutics position peaked at $368K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.